- Home
- EXAS vs SF Comparison
EXAS vs SF Comparison
Compare EXAS & SF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXAS
- SF
- Stock Information
- Founded
- EXAS 1995
- SF 1890
- Country
- EXAS United States
- SF United States
- Employees
- EXAS N/A
- SF N/A
- Industry
- EXAS Medical Specialities
- SF Investment Bankers/Brokers/Service
- Sector
- EXAS Health Care
- SF Finance
- Exchange
- EXAS Nasdaq
- SF Nasdaq
- Market Cap
- EXAS 10.1B
- SF 9.8B
- IPO Year
- EXAS N/A
- SF N/A
- Fundamental
- Price
- EXAS $48.49
- SF $112.69
- Analyst Decision
- EXAS Strong Buy
- SF Hold
- Analyst Count
- EXAS 20
- SF 9
- Target Price
- EXAS $70.26
- SF $112.38
- AVG Volume (30 Days)
- EXAS 2.6M
- SF 704.5K
- Earning Date
- EXAS 08-06-2025
- SF 07-30-2025
- Dividend Yield
- EXAS N/A
- SF 1.63%
- EPS Growth
- EXAS N/A
- SF 19.51
- EPS
- EXAS N/A
- SF 5.24
- Revenue
- EXAS $2,828,128,000.00
- SF $5,030,597,000.00
- Revenue This Year
- EXAS $14.61
- SF $8.07
- Revenue Next Year
- EXAS $12.65
- SF $10.55
- P/E Ratio
- EXAS N/A
- SF $21.49
- Revenue Growth
- EXAS 11.57
- SF 14.86
- 52 Week Low
- EXAS $39.97
- SF $73.27
- 52 Week High
- EXAS $72.83
- SF $120.64
- Technical
- Relative Strength Index (RSI)
- EXAS 38.76
- SF 70.32
- Support Level
- EXAS $48.15
- SF $108.16
- Resistance Level
- EXAS $53.95
- SF $111.14
- Average True Range (ATR)
- EXAS 2.10
- SF 2.13
- MACD
- EXAS -0.51
- SF -0.06
- Stochastic Oscillator
- EXAS 4.39
- SF 95.65
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
About SF Stifel Financial Corporation
Stifel Financial is a middle-market-focused investment bank that produces more than 90% of its revenue in the United States. Approximately 67% of the company's net revenue is derived from its global wealth management division, which supports over 2,000 financial advisors, with the remainder coming from its institutional securities business. Stifel has a history of being an active acquirer of other financial-services firms.